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In vivo role of cytochrome P450 2E1 and
glutathione-S-transferase activity for acrylamide toxicokinetics
in humans
Abstract
Acrylamide, a potential food carcinogen in humans, is biotransformed to the epoxide glycidamide in
vivo. Both acrylamide and glycidamide are conjugated with glutathione, possibly via
glutathione-S-transferases (GST), and bind covalently to proteins and nucleic acids. We investigated
acrylamide toxicokinetics in 16 healthy volunteers in a four-period change-over trial and evaluated the
respective role of cytochrome P450 2E1 (CYP2E1) and GSTs. Participants ingested self-prepared potato
chips containing acrylamide (1 mg) without comedication, after CYP2E1 inhibition (500 mg disulfiram,
single dose) or induction (48 g/d ethanol for 1 week), and were phenotyped for CYP2E1 with
chlorzoxazone (250 mg, single dose). Unchanged acrylamide and the mercapturic acids
N-acetyl-S-(2-carbamoylethyl)-cysteine (AAMA) and
N-acetyl-S-(2-hydroxy-2-carbamoylethyl)-cysteine (GAMA) accounted for urinary excretion [geometric
mean (percent coefficient of variation)] of 2.9% (42), 65% (23), and 1.7% (65) of the acrylamide dose in
the reference period. Hemoglobin adducts increased clearly following the acrylamide test-meal. The
cumulative amounts of acrylamide, AAMA, and GAMA excreted and increases in AA adducts changed
significantly during CYP2E1 blockade [point estimate (90% confidence interval)] to the 1.34-fold
(1.14-1.58), 1.18-fold (1.02-1.36), 0.44-fold (0.31-0.61), and 1.08-fold (1.02-1.15) of the reference
period, respectively, but were not changed significantly during moderate CYP2E1 induction. Individual
baseline CYP2E1 activity, CYP2E1*6, GSTP1 313A>G and 341T>C single nucleotide polymorphisms,
and GSTM1-and GSTT1-null genotypes had no major effect on acrylamide disposition. The changes in
acrylamide toxicokinetics upon CYP2E1 blockade provide evidence that CYP2E1 is a major but not the
only enzyme mediating acrylamide epoxidation in vivo to glycidamide in humans. No obvious genetic
risks or protective factors in xenobiotic-metabolizing enzymes could be determined for exposed
subjects.
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Abstract
Acrylamide, a potential food carcinogen in humans, is
biotransformed to the epoxide glycidamide in vivo .
Both acrylamide and glycidamide are conjugated with
glutathione, possibly via glutathione-S-transferases
(GST), and bind covalently to proteins and nucleic
acids. We investigated acrylamide toxicokinetics in 16
healthy volunteers in a four-period change-over trial
and evaluated the respective role of cytochrome P450
2E1 (CYP2E1) and GSTs. Participants ingested self-
prepared potato chips containing acrylamide (1 mg)
without comedication, after CYP2E1 inhibition (500 mg
disulfiram, single dose) or induction (48 g/d ethanol
for 1 week), and were phenotyped for CYP2E1
with chlorzoxazone (250 mg, single dose). Unchanged
acrylamide and the mercapturic acids N -acetyl-
S-(2-carbamoylethyl)-cysteine (AAMA) and N-acetyl-
S -(2-hydroxy-2-carbamoylethyl)-cysteine (GAMA)
accounted for urinary excretion [geometric mean (per-
cent coefficient of variation)] of 2.9% (42), 65% (23), and
1.7% (65) of the acrylamide dose in the reference period.
Hemoglobin adducts increased clearly following the
acrylamide test-meal. The cumulative amounts of
acrylamide, AAMA, and GAMA excreted and increases
in AA adducts changed significantly during CYP2E1
blockade [point estimate (90% confidence interval)] to
the 1.34-fold (1.14-1.58), 1.18-fold (1.02-1.36), 0.44-fold
(0.31-0.61), and 1.08-fold (1.02-1.15) of the reference
period, respectively, but were not changed significantly
during moderate CYP2E1 induction. Individual base-
line CYP2E1 activity, CYP2E1*6, GSTP1 313A>G and
341T>C single nucleotide polymorphisms, and GSTM1-
and GSTT1-null genotypes had no major effect on
acrylamide disposition. The changes in acrylamide
toxicokinetics upon CYP2E1 blockade provide evidence
that CYP2E1 is a major but not the only enzyme
mediating acrylamide epoxidation in vivo to glycida-
mide in humans. No obvious genetic risks or protective
factors in xenobiotic-metabolizing enzymes could be
determined for exposed subjects. (Cancer Epidemiol
Biomarkers Prev 2009;18(2):433–43)
Introduction
Acrylamide, an industrial and scientific chemical, is
present in high concentrations in some fried and baked
starch-enriched food (1, 2). The substance is carcinogenic
in rodents (2-4) and considered as a probable carcinogen
in humans (5). Dietary exposure to acrylamide affects all
nutritional patterns with different exposure levels across
age categories, countries, and composition of diet. Based
on food contents, the estimated acrylamide intake is
around 22 to 100 Ag/d (1, 6, 7).
Toxicokinetics of acrylamide were investigated mainly
in rodents, whereas recently, some data on acrylamide
disposition in healthy volunteers after acrylamide ad-
ministration in a test-meal (8, 9), in drinking water (10,
11), or dermally (12) have been published. As shown in
rats and mice (6, 10, 13) and in humans (8-10), acrylamide
is readily absorbed and widely distributed to tissues,
crosses the human placenta, and is transferred into the
breast milk (8, 14). Acrylamide is in part biotransformed
to the epoxide glycidamide. The extent of glycidamide
formation is dose and route dependent and it is highest
for low-dose dietary acrylamide exposure (15, 16).
Glycidamide is considered to be more genotoxic and
carcinogenic than acrylamide itself (3, 16-18). In mice, the
conversion of acrylamide to glycidamide is mediated by
cytochrome P450 2E1 (CYP2E1; refs. 19, 20), whereas
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respective human data in vivo are lacking. Whereas the
low molecular weight and the high hydrophilicity and
reactivity of glycidamide make in vitro studies on this
metabolic step difficult, a recent report showed that in
expressed human cytochrome P450s, in liver micro-
somes, and in CYP expressing cell lines CYP2E1 is
involved in glycidamide formation (21).
Acrylamide and glycidamide are conjugated to gluta-
thione, which is the main pathway of acrylamide
metabolism in both rodents and humans (10-12, 22-24).
As products of this conjugation, the following mercaptu-
ric acid metabolites have been observed: N-acetyl-S-(2-
carbamoylethyl)-cysteine (AAMA); N-acetyl-S-(2-carba-
moylethyl)-cysteine-S -oxide; N -(R,S )-acetyl-S -(2-hy-
droxy-2-carbamoylethyl)-cysteine (GAMA); and N -
acetyl-S -(1-carbamoyl-2-hydroxyethyl)-cysteine. Of
these, AAMA, its sulfoxide, and GAMA have been
unequivocally confirmed in humans (9-11). Whereas
there are many glutathione-S-transferases (GST) in
humans and rodents, which may be involved in these
metabolic steps, nonenzymatic formation of glutathione
conjugates is also possible and has been reported for
acrylamide (25, 26). The role of GSTs in acrylamide
metabolism in humans remains to be assessed.
Acrylamide and glycidamide have the capability to
bind covalently to nucleophilic sites of proteins and
nucleic acids (10, 20, 27, 28). Carcinogenicity studies in
rats indicate that chronic acrylamide exposure increased
the incidence of various tumor types (3, 5, 29) from the
dose of 0.5 mg/kg/d, which would correspond to a
human equivalent dose of 7.6 Ag/kg/d (29). Based on
rodent studies, the cancer risk for humans through the
dietary acrylamide was estimated to be 0.3  103 to
2.4  103 by lifetime acrylamide uptake of 70 Ag/d with
f8-fold range of estimates driven by different cancer
potency values and extrapolation models (6, 7, 13).
Equivocal results on the relationship between dietary
acrylamide and cancer incidence/mortality have been
reported in epidemiologic studies (3, 13, 30, 31). A
recently conducted case-control study showed a statisti-
cally significant correlation between levels of AA adduct
to hemoglobin and breast cancer with an estimated
incidence rate ratio of 2.7 (95% confidence interval, 1.1-
6.6) per 10-fold increase in adduct level (32).
Based on urinary excretion data and levels of
acrylamide and glycidamide adducts to hemoglobin,
the extent of glycidamide formation and the estimated
internal exposure to glycidamide, which is considered to
play the main role in acrylamide carcinogenicity (16-18),
are about two to four times lower in humans compared
with rodents (9, 10). In humans, the urinary concentra-
tion ratio of AAMA and GAMA, which is considered as a
metric to describe the extent of conversion of acrylamide
to glycidamide (9) and thus reflects internal exposure,
varies considerably between subjects (22, 23). It is unclear
to which extent the activity and expression of metabo-
lizing enzymes influences acrylamide metabolism and,
therefore, contributes to differences in acrylamide dis-
position and carcinogenicity among species and between
individuals (20, 33). The objectives of the present study
were to clarify the role of CYP2E1 and GSTs and their
genetic variants for the in vivo metabolism of acrylamide
in humans and, thus, to improve the cancer risk
assessment for humans through acrylamide intake with
food.
Volunteers and Methods
Study Design and Study Participants. The study was
conducted according to the pertinent version of the
Declaration of Helsinki and was approved by the Ethics
Committee of the University of Cologne. All volunteers
provided written informed consent. The study had a
single-center, four-period cross-over design. In three of
the four study periods, participants ingested a single
acrylamide-containing test-meal (potato chips), which
was given without comedication (reference period), after
CYP2E1 inhibition with disulfiram (inhibition period) or
after CYP2E1 induction with ethanol (induction period).
Baseline CYP2E1 activity was determined in a fourth
period using chlorzoxazone. The washout phase between
treatments lasted 2 wk.
Despite the exploratory character of the study, the
following considerations were made for selection of the
sample size: On the basis of a conservative estimate of
intrasubject multiplicative coefficients of variation (CV)
of up to 30% for acrylamide metrics, a sample size of
N = 16 would allow rejection of the respective null
hypothesis ‘‘presence of a more than 0.7 or 1.43-fold
change in acrylamide metrics by disulfiram or by ethanol
intake’’ with a = 0.05 and a power of at least 80% for all
parameters if the true mean changes were not outside the
0.95- to 1.05-fold range (34). To assess the relationship
between chlorzoxazone and acrylamid kinetics, a sample
size of 16 is sufficient to show an r2 of 0.5 with a = 0.05
and a power of at least 80% (indicating that at least 50%
in the variation of the respective acrylamide parameter
would be related to individual variation in CYP2E1
activity). Thus, eight females and eight male Caucasian
nonsmokers were included in the study; age (mean F
SD) was 29.8F 5.9 y and the body mass index was 22.9F
2.0 kg/m2. Participants were required to be healthy as
determined by medical history and physical examination
including electrocardiogram, vital sign measurements,
standard clinical chemistry, and hematologic evaluation.
Main exclusion criteria were pregnancy or lactation in
females, environmental or occupational exposure to
acrylamide, alcohol consumption of >30 g/d, concomi-
tant drug intake, and suspicion of hypersensitivity to
chlorzoxazone and disulfiram. The volunteers were
instructed to abstain from acrylamide-rich foodstuffs
(in particular, potato chips, pan-fried potatoes, biscuits,
crackers, and breakfast cereals), alcohol, methylxanthine-
containing food and beverages, grapefruit flesh/juice,
and any other comedication before and during the study.
The volunteers were hospitalized 11 h before acryl-
amide or chlorzoxazone administration and until 12 h
(chlorzoxazone period) or 24 h (all other periods)
thereafter. In each study period, they had to fast from
11 h before dosing (except disulfiram administration) and
until 6 h post-dose, whereas fluid intake was standard-
ized from 1 h to +6 h relative to the dose. Daily fluid
intake up to 72 h post-dose should not exceed 3 liters.
Acrylamide-containing food was prepared by frying
batches of potato chips on the day before administration
as previously described (9). Acrylamide concentration in
the processed potato chips was determined by liquid
chromatography/tandem mass spectrometry (LC-MS/
MS) and appropriate portions were given to ensure the
acrylamide target dose. In the acrylamide periods, each
participant ingested potato chips with 240 mL of water.
Toxicokinetics and Toxicogenetics of Acrylamide
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The true acrylamide doses administered reached a
median value of 998 Ag (range, 957-1,000 Ag) or 14.0 Amol
mol corresponding to 14.8 Ag/kg body weight.
For CYP2E1 inhibition, volunteers received a single
oral dose of 500 mg disulfiram (Antabus 0.5 Disperget-
ten, Altana Pharma AG) 10 h before acrylamide dosing
and after at least 1 h of fasting. For CYP2E1 induction,
participants drunk two bottles (0.5 liter) of beer every
evening (Reissdorf Ko¨lsch, Privat-Brauerei Heinrich
Reissdorf & Co.) containing 48 mL of ethanol/L during
the 7 d before acrylamide administration. Beer intake
was ambulatory; regularity, completeness, timing, and
tolerability of beer intake were assessed based on the
subject’s diary and checked by study personnel. The
CYP2E1 phenotype was investigated by using a single
oral dose of 250 mg chlorzoxazone (Chlorzoxazone,
AstraZeneca).
Blood samples for phenotyping were collected just
before chlorzoxazone dosing and 2 h thereafter using Li+-
heparinized tubes (Sarstedt). The samples were centri-
fuged (2,000  g , +4jC, 10 min), frozen, and stored at
80jC until assayed. Blood sampling for determination
of acrylamide and glycidamide adducts to hemoglobin
was carried out just before administration and at 24 h
post-dose using EDTA-containing tubes (Sarstedt). The
samples were initially centrifuged for isolation of
erythrocytes (1,992  g , +4jC, 5 min). For hemoglobin
isolation, erythrocytes were washed thrice with 2.0 mL of
0.9% NaCl solution. Hemolysis was achieved by addition
of pure water (2.0 mL) and pulse-vortexing (27). The
sample was placed in a 15-mL Falcon tube and stored at
20jC or below until analysis. For genotyping, a blood
sample from each volunteer was drawn at pre-study
examination using EDTA-containing tube (Sarstedt) and
stored at 20jC. For determination of urinary acrylam-
ide and acrylamide derived metabolites, samples of urine
were collected just before dosing and for the following
intervals: 0-2, 2-4, 4-6, 6-8, 8-10, 10-12, 12-16, 16-24, 24-36,
36-48, and 48-72 h post-dose. Urine was kept at +4jC
during the collection period and subsequently stored at
80jC until analysis.
The well-being of the study subjects was closely
surveyed throughout the study by measuring vital signs
and recording of any adverse event.
Analytic Assays. Acrylamide in chips samples was
quantified by LC-MS/MS method (lower limit of
quantification, LLQ: 140.7 nmol/L) as previously
reported (35) using a Thermo Finnigan LC-MS/MS-
System (Thermo Finnigan). Unmetabolized acrylamide
in urine was analyzed by LC-MS/MS (LLQ: 7.0 nmol/L)
using an Applied Biosystems API3000 LC-MS/MS
device as previously described (8). Quantification of
AAMA and GAMA in urine was done according to the
method previously described (22, 36) with modifications.
Briefly, 50 AL of 1 N HCl and 50 AL of labeled internal
standard (d3-AAMA) were added to 1,200 AL of urine.
The samples were vortexed and centrifuged (14,000  g ,
5 min). The supernatant (1,000 AL) was placed onto an
SPE column [Isolute ENV+, 50 mg, 10 mL XL (Separtis)]
preconditioned with 4 mL methanol, 2 mL formic acid
(pH 2.0), and 2 mL water. Afterwards, the columns were
washed with 1,200 AL HCl (pH 2.5). The analytes were
eluted with 1,200 AL of 2% (v/v) formic acid in methanol
and evaporated to dryness. The pellets were redissolved
in 100 AL of 0.1% formic acid/10% methanol (v/v), and
20 AL were injected into the LC-MS/MS system (Thermo
Finnigan). Chromatography was done in 6 min using a
50  2.1 mm, 5-AmHypercarb column (Thermo Hypersil-
Keystone) with a 10  4.0 mm, 5-Am Hypercarb pre-
column and a linear gradient of methanol and formic
acid (0.1%). AAMA and GAMA were detected by
negative electrospray ionization in the selected reaction
monitoring mode with ion transitions (m/z) 233.0!104.0
and 249.0!120.0 for AAMA and GAMA, respectively.
The LLQs were 21.3 and 20.0 nmol/L for AAMA and
GAMA, respectively. Calibration curves were linear
between 20 and 20,000 nmol/L. Intraday and interday
precision values did not exceed 11.3% and 10.3% for
AAMA and GAMA, respectively; intraday and interday
accuracy ranged from 3.7 to +6.8% for AAMA and from
0.7 to 6.8% for GAMA.
The analysis of acrylamide (AAVal) and glycidamide
(GAVal) adducts to the NH2-terminal valine of hemo-
globin was carried out by gas chromatography-MS as
previously described (37-41). The analysis was done
using an Agilent Technologies 6890 N Network GC
System [column, DB-XLB, 30 m  0.25 mm ID, 0.25 Am
film thickness (J&W Scientific); helium flow, 1.3 mL/min;
injector, PTV injector used in pulsed splitless mode at
250jC; injection volume, 1 AL; temperature program:
90jC for 1 min, 25jC/min to 210jC, 10jC/min to 240jC,
25jC/min to 310jC for 5 min] coupled to 5973 inert Mass
Selective Detector device (Agilent Technologies) operat-
ing in negative chemical ionization mode (reactant gas,
methane (45%); ion source temperature, 150jC; quadru-
pole temperature, 150jC; transfer line temperature,
280jC). Hb adducts were determined as pentafluorophe-
nylthiohydantoin (PFPTH) derivatives subsequent to the
modified Edman degradation procedure (27, 38, 39). As
internal standards for AAVal and GAVal, deuterium-
labeled d7-AAVal-PFPTH and d7-acGAVal-PFPTH
(quantification is based on the acetonized derivative d7-
acGAVal-PFPTH; ref. 39) were used. Standards were
synthesized at the Department of Food Chemistry and
Environmental Toxicology, University of Kaiserslautern,
Germany as described (37, 42). The LLQs were 0.9 and
2.3 pmol/g Hb for AAVal and GAVal, respectively.
Intraday and interday precision values were below 9.6%
and 12.8% for AAVal and GAVal, respectively; intraday
and interday accuracy ranged from 2.0% to 8.7% for
AAVal and from 7.2% to 14.6% for GAVal. In the
calibration range of 0.25 to 250 nmol/L, linearity was
characterized by r2 = 0.9981 for d7-AAVal-PFPTH and
r2 = 0.9996 for d7-acGAVal-PFPTH.
Chlorzoxazone and 6-OH-chlorzoxazone in plasma
for CYP2E1 phenotyping were determined by a high-
performance liquid chromatography method (43) with
modifications. The high-performance liquid chromatog-
raphy system consisted of a Waters 2690 Separations
Module with a PDA Waters 996 photodiode array
detector. Internal standard [3-isobutyl-1-methylxanthine
(IBMX), 50 AL, 200 Ag/mL] was added to 500 AL of
plasma; plasma proteins were precipitated; samples
were centrifugated (4jC, 16,000  g , 20 min); and the
supernatant was evaporated to dryness. Thereafter, the
pellets were redissolved in 100 AL of mobile phase
[acetonitrile/acetate buffer (20:80, v/v, 0.05 mol/L, pH
4.25)], and 30 AL were injected onto a 250  4.6 mm,
5-Am, Zorbax RX-C8 column (Duratec Analysentechnik)
Cancer Epidemiology, Biomarkers & Prevention
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with a Zorbax RX-C8 12.5  4.6 mm pre-column.
Chlorzoxazone, 6-OH-chlorzoxazone, and IBMX were
detected at 279, 296, and 272 nm, respectively. Calibra-
tion curves were linear over a concentration range of
3.2 to 235.9 mmol/mL and 2.6 to 215.6 mmol/mL for
chlorzoxazone and 6-OH-chlorzoxazone, respectively,
and corresponding LLQs were 3.2 and 2.6 mmol/mL.
The interday and intraday accuracy ranged from 7.8%
to +6.1% for chlorzoxazone and from 1.4% to +2.7% for
6-OH-chlorzoxazone. Precision was below 5.7% and
1.9% for chlorzoxazone and 6-OH-chlorzoxazone,
respectively.
Genetic Analysis. Genetic analysis included the
investigation of CYP2E1*5A (Pst I+, RsaI, Dra I),
CYP2E1*5B (Pst I+, Rsa I), and CYP2E1*6 (Dra I)
alleles; null alleles of GSTM1 (GSTM1*0) and GSTT1
(GSTT1*0) genes; and GSTP1 313A>G and GSTP1
341T>C single nucleotide polymorphisms (SNP).
DNA was isolated from EDTA anticoagulated blood
using the QIAamp DNA Blood Mini Kit (Qiagen)
following the manufacturer’s instructions. A 300-AL
aliquot of a whole blood sample yielded, on average,
5 Ag of DNA in 100 AL eluting buffer (50 ng/AL), which
was in accordance with the value indicated by the
manufacturer. All PCR amplifications were run in a
MultiCycler programmable thermal cycler-200 (MJ Re-
search Laboratories).
CYP2E1 genotyping was carried out with the PCR-
RFLP method as previously reported (44) with modifi-
cations. The PCR reaction mixture (50-AL) consisted of
genomic DNA (200 ng), PCR buffer (10), MgCl2 (25
mmol/L), deoxynucleotide triphosphates (10 mmol/L),
each primer (50 Amol/L), GoTaq DNA-polymerase (2.5
units; Qiagen), and water for molecular biology analysis.
For investigation of the PstI and RsaI restriction sites
with a complete linkage disequilibrium (45), primer pair
5 ¶-CCAGTCGAGTCTACATTGTCA-3 ¶ and 5 ¶-
TTCATTCTGTCTTCTAACTGG-3¶was used, which pro-
duced a 410-bp fragment. For the Dral restriction site,
primer pair 5¶-TCGTCAGTTCCTGAAAGCAGG-3¶ and
5¶-GAGCTCTGATGCAAGTATCGCA-3¶ was used,
which yielded a 995-bp DNA fragment. An initial
denaturation (94jC, 1 min) was followed by 31 cycles
of denaturation (94jC, 30 s), annealing (55jC, 1 min), and
elongation (72jC, 1 min), with a final elongation at 72jC
for 10 min. PCR products were separated electrophoret-
ically on a 1.6% agarose gel (90 mV, 60 min). Each PCR
product (17.5 AL) was digested with 10 units of
restriction enzymes RsaI and PstI for 410-bp fragments
and DraI for 996-bp fragments, respectively, in a Tango
buffer (5) at 37jC for 60 min. The incubation products
were separated electrophoretically on a 1.6% agarose gel
(90 mV, 60 min). The presence of the PstI restriction site
yielded two fragments (290 and 120 bp) of the 410-bp
PCR product. In contrast, the presence of the RsaI
restriction site yielded two fragments (60 and 350 bp)
with the 410-bp PCR product, whereas in this case it was
not digested by PstI. The 995-bp PCR product with the
polymorphic Dral restriction site and the wild-type allele
was digested by DraI into two (874 and 121 bp) and three
(572, 302, and 121 bp) fragments, respectively.
Genotyping for GSTs was done using direct sequenc-
ing methods (46, 47) with modifications. The PCR
reaction mixture (50 AL) consisted of genomic DNA
(100-200 ng), PCR buffer (10), MgCl2 (25 mmol/L),
deoxynucleotide triphosphates (10 mmol/L), each prim-
er (50 Amol/L; Table 1), GoTaq DNA-polymerase
(2.5 units; Qiagen), and pure water. After amplification
(Table 1), the PCR products were separated electropho-
retically (90 mV, 60 min) on a 1.6% agarose gel. The
allele-specific PCR method used for GSTM1 and GSTT1
genotyping allowed the identification of the active *A-
allele(s) without discrimination between homozygous
and heterozygous alleles. In such a case, the 650-bp
(GSTM1) or 480-bp (GSTT1) DNA fragments were
amplified by PCR. In the absence of active *A-allele(s)
of these genes (null type, *0/*0), no DNA fragments were
Table 1. Methods for GST genotyping
Primers and PCR conditions used for DNA amplification of GSTM1 and GSTT1
Gene GSTM1 GSTT1
Forward-Primer GAACTCCCTGAAAAGCTAAAGC TTCCTTACTGGTCCTCACATCTC
Reverse-Primer CATGCGAGTTATTCTGTGTGAGC TCACCGGATCATGGCCAGCA
Fragment (bp) 650 480
PCR program Initial denaturation 1 min at 94jC 31 cycles 2 min at 94jC 31 cycles
Denaturation 1 min at 94jC 30 s at 94jC
Annealing 1 min at 55jC 30 s at 58jC
Elongation 1 min at 72jC 1 min at 72jC
Final elongation 10 min at 72jC 10 min at 72jC
Primers and PCR conditions used for DNA amplification of GSTP1
Gene GSTP1 313A>G GSTP1 341C>T
Forward-Primer ACCCCAGGGCTCTATGGGAA AAGCAGAGGAGAATCTGGGACTC
Reverse-Primer TGAGGGCACAAGAAGCCCCT CTAAGCCCATCCCCTAGGTC
Fragment (bp) 175 323
PCR program Initial denaturation 30 s at 94jC 31 cycles 1 min at 94jC 31 cycles
Denaturation 30 s at 94jC 30 s at 94jC
Annealing 15 s at 58jC 30 s at 57jC
Elongation 1 min at 72jC 30 s at 72jC
Final elongation 10 min at 72jC 10 min at 72jC
Toxicokinetics and Toxicogenetics of Acrylamide
Cancer Epidemiol Biomarkers Prev 2009;18(2). February 2009
436
amplified. For GSTP1 genotyping, the PCR products
were purified using Promega Wizard SV Gel and PCR
Clean-Up System (Promega) according to the manufac-
turer’s instructions. DNA sequencing was carried out
using BigDye Terminator kit V.1.1 (Applied Biosystems).
The reaction mixture (10 AL) for sequencing PCR
consisted of purified PCR products (6 AL, 50 ng of
DNA), sequencing primers [3.2 Amol/L; GSTP1 313A>G
(ACCCCAGGGCTCTATGGGAA) and GSTP1 341T>C
(GGCCAGATGCTCACCTGGTC)], and BigDye Termi-
nator Mix (2 AL). PCR included 29 cycles, each consisting
of denaturation (96jC, 30 s), annealing (50jC, 30 s), and
elongation (60jC, 4 min), followed by final elongation
(62jC, 10 min). The sequencing products were purified
with Sephadex G50 (Sigma) on MultiScreen HV plates
(MAHVN030, Millipore) according to the manufac-
turer’s instructions. Capillary electrophoresis was car-
ried out using an ABI Prism 3100 Genetic Analyzer
sequencer (Applied Biosystems). Pairwise sequence
comparison with reference sequences was done with
MT Navigator PPC and Edit View 1.0.1 Software
(Applied Biosystems).
Synthesis of Reference Material. For epoxidation of
acrylamide to form glycidamide, a catalytical system
[1,4,7-trimethyl-1,4,7-triazacyclononan and sodium
ascorbate (Mn-TMTACN)], developed by Berkessel
et al. (48, 49), was used. Acrylamide (2.84 g; 40.0 mmoL,
1 eq) was dissolved in 25.00 mL of acetonitrile and cooled
down to 0jC. Afterwards, 20.00 mL of a 35% H2O2
solution were added to the mixture. Within 3 h, while
stirring and cooling with ice, a mixture of 5.00 mL of a
40.00 mmol/L trimethyltriazacyclononane solution in
acetonitrile, 2.50 mL of a 80.00 mmol/L aqueous sodium
ascorbate solution, and 0.40 mL of a 160 mmol/L
aqueous Mn (II)-acetate solution was added dropwise
to the acrylamide solution. The clear solution turned
brown. The solution was stirred overnight while warm-
ing from 0jC to ambient temperature. MnO2 was added
to the solution until gas production receded. The aqueous
phase was filtered, extracted thrice with 20.00 mL ethyl
acetate, the organic phases dried with MgSO4, and the
solvent in vacuo removed [glycidamide: melting point,
40jC; 1H nuclear magnetic resonance (300 MHz, DMSO-
d6): d = 2.74 (dd, J = 6, 2.4 Hz; 1 H, H-C3), 2.86 (dd, J = 6,
4.2 Hz; 1 H, H¶-C3), 3.27 (dd, J = 4.2, 2.4, 1 H, H-C2), 7.36
(d, J = 41.7, 2 H, NH2);
13C nuclear magnetic resonance
(75 MHz, DMSO-d6): d = 45.44 (t, C-3), 48.26 (d, C-2),
169.98 (s, C-1); EA: C3H5NO2: calculated: C, 41.38; H, 5.79;
N, 16.09, O, 36.75; found: C, 41.19, H, 5.81, N, 15.37].
The yield of glycidamide was 43% and no impurities
were present in the 1H nuclear magnetic resonance
spectrum. The subsequent synthesis of GAMA, AAMA,
and d3-AAMA was done as described (24).
Data Analysis. Noncompartmental urinary toxicoki-
netic parameters of acrylamide and its metabolites were
evaluated as described elsewhere (9). The molar plasma
concentration ratio 6-OH-chlorzoxazone/chlorzoxazone
at 2 h post-dose was applied as phenotyping metric for
CYP2E1 (50, 51). Testing for an effect of disulfiram or
ethanol on acrylamide toxicokinetics was handled as an
equivalence problem; thus, point estimates and 90%
confidence intervals were calculated for the ratios of
toxicokinetic parameters between periods (52). An effect
was considered to be statistically significant if the 90%
confidence interval of the estimated true ratio l test/
lreference did not include unity. Changes of hemoglobin
adducts were assessed by a t test for paired data applied
on log values. Linear regression analysis was used to
investigate the relationship between CYP2E1 phenotype
and acrylamide toxicokinetics and that between blood
and urinary toxicokinetic parameters. Tests for differ-
ences between CYP2E1, GSTM1, T1 , and P1 genotypes
with regard to acrylamide toxicokinetics were carried out
using the Kruskal-Wallis-test. Statistical analysis was
done using SPSS for Windows version 15.0. Significance
for the latter tests was assumed at P < 0.05.
Results
Toxicokinetics of Acrylamide. Because of the ubiqui-
tous exposure to acrylamide, in five of the pre-dose
samples quantifiable amounts of acrylamide and/or its
metabolites were found. In all study periods, following
acrylamide intake, maximal urinary excretion rates
during the 2 to 4 hours and 6 to 10 hours of collection
period were observed for unchanged acrylamide and its
metabolites (AAMA and GAMA), respectively (Table 2).
One volunteer (#10) had unusual concentration-time
profiles for GAMA in the reference and the inhibition
periods; low GAMA excretion rates up to 12 to 16 hours
post-dose with subsequent increasing until the end of
urine collection period (72 hours post-dose) were
observed. Because the excretion profiles of unchanged
acrylamide and AAMA did not show any abnormalities
in this volunteer and were similar to those in other study
subjects, there was no clear evidence for an additional
exposure to acrylamide after intake of the test meal. The
reason for this discrepancy remains unexplained. Be-
cause a reasonable assessment of elimination half-life
was not possible in this case, the data from this subject
were excluded from parts of the calculation of some
GAMA toxicokinetics and statistical evaluation (Table 2).
Compared with the reference period, disulfiram
coadministration resulted in clear and significant
changes in acrylamide toxicokinetics (Table 2; Fig. 1).
Average cumulative acrylamide excretion extrapolated
to infinity increased 1.34-fold and AAMA excretion
increased 1.15-fold, whereas GAMA excretion was
reduced to 0.44-fold of the respective values in the
reference period. In contrast, CYP2E1 induction with
ethanol did not result in significant changes in toxicoki-
netics (Table 2, Fig. 1). The ratios for the CYP2E1
induction period over the reference period were 1.00,
0.99, and 1.04 for acrylamide, AAMA, and GAMA,
respectively. Likewise, the molar ratio of GAMA/AAMA
for cumulative acrylamide excretion dropped signifi-
cantly in the inhibition period but was similar in the
reference and in the induction periods (Table 2). As the
sum of unchanged acrylamide, AAMA, and GAMA,
the cumulative urinary recovery reached 71% (CV 23%),
81% (CV 41%), and 70% (CV 31%) of the acrylamide
dose. Thus, the changes in the CYP2E1 inhibition period
resulted in clear increase in the recovery of the
acrylamide dose.
At 24 hours after intake of the acrylamide-rich meal,
increased mean concentrations of both AAVal and
GAVal were observed in all study periods (Table 3).
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Table 2. Urinary excretion of acrylamide and its mercapturic acid metabolites following intake of 1 mg (geometric mean dose: 13.9 Mmol) of acrylamide in
a test meal (n = 16)
Parameter (unit) Study period Comparison between periods
Reference* CYP2E1 inhibition* CYP2E1 induction* CYP2E1 inhibition
c
CYP2E1 induction
c
Time of maximal AA 2.3 (51%) [2.9 (0.9-4.9)] 3.0 (17%) [2.9 (2.8-4.9)] 2.6 (45%) [2.9 (0.9-4.9)] 0.72 h (0.23-1.22 h) 0.36 h (0.13-0.86 h)
urinary excretion AAMA 6.6 (29%) [6.8 (4.8-10.8)] 8.7 (32%) [8.9 (4.9-13.9)] 7.0 (30%) [6.9 (4.9-10.8)] 2.07 h (0.92-3.21 h) 0.37 h (0.77-1.52 h)
rate (h)
b
GAMA 8.6 (73%) [6.9 (2.9-29.9)] 8.3 (115%) [4.9 (0.9-42.0)] 8.3 (56%) [6.9 (2.9-19.9)] 0.36 h (3.45-2.73 h) 0.32 h (3.41-2.77 h)
Maximal urinary AA 71 (37%) [71 (33-138)] 89 (39%) [88 (56-209)] 69 (31%) [71 (37-116)] 126% (108-148%) 98 (83-115%)
excretion rate AAMA 426 (34%) [411 (258-983)] 499 (51%) [514 (152-1,111)] 428 (34%) [429 (227-731)] 117% (96-143%) 101% (82-123%)
(nmol/h) GAMA 12.9 (74%) [11.9 (3.4-58.4)] 9.6 (86%) [9.7 (2.5-40.3)] 12.8 (71%) [13.3 (5.8-30.1)] 75% (55-102%) 100% (73-135%)
Apparent terminal AA 5.0 (84%) [4.0 (2.3-25.1)] 6.8 (73%) [7.5 (1.7-22.4)] 5.3 (79%) [4.6 (2.3-19.3)] 137% (93-200%) 106% (72-156%)
elimination AAMA 25.4 (39%) [23.5 (14.7-55.7)] 21.8 (40%) [19.5 (11.3-53.8)] 25.4 (42%) [23.4 (14.4-62.9)] 86% (71-104%) 100% (83-121%)
half-life (h) GAMAx 19.6 (69%) [20.7 (8.8-49.0)] 13.6 (103%) [15.8 (2.3-51.7)] 19.1 (93%) [21.7 (3.4-66.6)] 68% (41-112%) 93% (57-152%)
Ae up to 72 h AA 2.9 (44%) [2.9 (1.2-6.0)] 3.9 (41%) [3.5 (2.2-9.5)] 2.9 (33%) [3.0 (1.5-5.3)] 135% (114-159%) 101% (86-119%)
post-dose AAMA 58 (23%) [61 (39-83)] 69 (43%) [72 (31-137)] 57 (32%) [64 (34-87)] 119% (104-137%) 99% (86-114%)
(molar % of dose) GAMA 1.4 (68%) [1.4 (0.5-4.6)] 0.6 (142%) [0.5 (0.1-2.3)] 1.4 (55%) [1.4 (0.5-3.0)] 40% (29-56%) 99% (71-137%)
AA+ AAMA+GAMA 63 (24%) [65 (42-92)] 74 (41%) [75 (36-145)] 62 (31%) [69 (38-91)] 119% (104-136%) 99% (86-113%)
GAMA/AAMA 0.0241 (61%)
[0.0244 (0.0090-0.0739)]
0.0081 (189%)
[0.0066 (0.0013-0.0596)]
0.0241 (46%)
[0.0242 (0.0090-0.0485)]
34% (23-49%) 100% (69-145%)
Ae extrapolated AA 2.9 (42%) [2.9 (1.3-6.0)] 3.9 (41%) [3.5 (2.2-9.5)] 2.9 (33%) [3.0 (1.6-5.3)] 134% (114-158%) 100% (85-118%)
to infinity AAMA 65 (23%) [66 (44-95)] 77 (43%) [80 (32-162)] 65 (32%) [76 (36-98)] 118% (102-136%) 99% (86-115%)
(molar % of dose) GAMAx 1.7 (65%) [1.7 (0.6-4.9)] 0.8 (109%) [0.8 (0.2-2.6)] 1.8 (61%) [1.9 (0.7-5.5)] 44% (31-61%) 104% (75-145%)
AA+ AAMA+GAMAx 71 (23%) [71 (48-104)] 81 (41%) [80 (37-169)] 70 (31%) [82 (42-104)] 115% (100-132%) 100% (86-115%)
GAMA/AAMAx 0.0263 (63%)
[0.0260 (0.0105-0.0739)]
0.0100 (148%)
[0.0085 (0.0019-0.0658)]
0.0278 (56%)
[0.0247 (0.0122-0.0740)]
38% (25-57%) 104% (70-156%)
NOTE: Significant differences between periods (i.e., unity for ratios and zero for differences not included in the confidence interval) are in boldface.
Abbreviations: Ae, amounts excreted in urine; AA, unchanged acrylamide; AAMA, N -acetyl-S -(2-carbamoylethyl)-cysteine; GAMA, N -acetyl-S-(2-hydroxy-2-carbamoylethyl)-cysteine.
*Values are shown as geometric means (CV%) and [median (range)].
cValues are shown as point estimate and 90% confidence interval for the percent ratio (time of maximal excretion: difference) relative to the reference period.
bAdditive model.
xn = 15 for reference and CYP2E1 inhibition period.
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This increase was significant in all periods for AAVal
when evaluated separately and was significant for
GAVal only when evaluating all periods together.
Compared with the reference period, CYP2E1 inhibition
significantly increased the formation of AAVal to
the 1.08-fold, whereas CYP2E1 induction had no effect
(Table 3). No clear effects of CYP2E1 inhibition or in-
duction was observed in the +24 h/pre-dose GAVal ratios.
Baseline CYP2E1 Activity and Toxicogenetics of
Acrylamide. The frequencies of CYP2E1 and GST
genotypes detected by study subjects are shown in
Table 4. The molar ratio of 6-OH-chlorzoxazone/chlor-
zoxazone in plasma used as a CYP2E1 phenotyping
metric was (geometric mean and CV%) 0.33 (49%). This
parameter showed no significant differences between
CYP2E1 genetic variants. In addition, CYP2E1 variants
had no clear effect on any toxicokinetic parameter of
acrylamide, and baseline CYP2E1 activity had no
significant correlation to toxicokinetic parameters of
acrylamide (all P > 0.05). Furthermore, there was no
obvious difference in toxicokinetics of acrylamide be-
tween the investigated GSTs genotypes (Fig. 2), and even
the absence of alleles coding for active GSTM1 or GSTT1
variants had no effect. Comparison of all the toxicoki-
netic parameters between genotypes occasionally gave
significant differences for individual study periods but
with no consistent pattern, suggesting that this is a
chance finding.
Tolerability of Treatment. The acrylamide-containing
meal and all study medications were well tolerated; there
were no adverse events with relevant effect on the well-
being of study participants or affecting study conduction.
Discussion
In the present study, the toxicokinetic parameters of
acrylamide were investigated following administration
of a test-meal containing 1 mg acrylamide to healthy
volunteers, and the role of CYP2E1 activity and GSTs and
their genetic variants for the in vivo metabolism of
acrylamide was evaluated. We found that acrylamide
intake increases concentrations of acrylamide and glyci-
damide hemoglobin adducts and that cotreatment with
disulfiram resulting in CYP2E1 blockade was related to a
shift in acrylamide metabolism from glycidamide forma-
tion to increased formation of acrylamide mercapturic
acid and acrylamide adducts to hemoglobin.
With respect to the metabolic pattern of acrylamide
and total dose recovery in the reference period, the
toxicokinetic parameters were in accordance to the data
from other human studies with acrylamide dosing (9-12).
For the disulfiram period, almost complete inhibition of
CYP2E1 by the drug is expected. After a single oral dose
of 500 mg disulfiram, CYP2E1 activity inhibitions of
z90% at the time point of acrylamide administration and
f50% at 72 hours post-dose have been described (53).
Disulfiram coadministration resulted in an increase of
the cumulative amounts of unchanged acrylamide and
AAMA and a decrease of glycidamide excreted in urine,
accompanied by an enhanced formation of AAVal. These
results indicate that disulfiram inhibits the oxidative
metabolism of acrylamide and, therefore, provide some
in vivo evidence for the involvement of CYP2E1 in the
conversion of acrylamide to glycidamide in humans,
which is in concordance with recent in vitro data (21).
Considering the quantitative changes in excretion of
acrylamide and both metabolites by CYP2E1 inhibition,
Figure 1. Cumulative urinary excretion of unchanged acryl-
amide (A), AAMA (B), and GAMA (C) up to 72 h after
administration of 14 Amol of acrylamide (geometric means).
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this enzyme may account for approximately one fourth
of primary acrylamide metabolism. These data also show
clearly that other enzyme(s) make a substantial contri-
bution to glycidamide formation in humans. A caveat,
however, is to be considered with regard to disulfiram
selectivity, which is not only a selective inhibitor within
the group of cytochrome P450 enzymes (54) but also
inhibits (directly or via metabolites) aldehyde dehydro-
genases (55), P-glycoprotein (56), and dopamine h-
hydroxylase (57), as well as proteasome activity (58).
Whereas the chemical nature of glycidamide as an
oxidation product of acrylamide favors a role of CYP2E1
versus the other disulfiram targets, it cannot be excluded
that inhibition of enzymes other than CYP2E1 may have
contributed to the disulfiram effect on acrylamide
toxicokinetics. Irrespective of the enzymes involved, it
is currently under discussion whether disulfiram would
be useful to diminish the formation of the more toxic
glycidamide by subjects occupationally exposed to
acrylamide (53); however, because disulfiram increases
acrylamide adduct formation, it is doubtful whether this
approach provides any benefit.
Interestingly, the overall recovery of an acrylamide
dose when coadministered with disulfiram increased
clearly. This prompts the speculation that additional
undetected, probably small-molecule metabolites beyond
glycidamide (including secondary glycidamide metabo-
lites such as glycidamide diol) are formed (10, 23) by the
enzymes inhibited by disulfiram (assumed to be
CYP2E1). It is also possible that in the absence of
disulfiram, a major fraction of acrylamide is metabolized
to glycidamide, which then is bound rapidly to macro-
molecules and therefore is not available for excretion as
GAMA. This is, however, not reflected in hemoglobin
adducts but may occur in the tissues where glycidamide
is formed.
To investigate the toxicokinetics of acrylamide on
CYP2E1 induction as an independent approach to change
CYP2E1 activity, ethanol was administered in the current
study. Following ethanol consumption of 48 g/d for
Table 4. CYP2E1 and GST genotypes of study participants
Polymorphism Homozygous (wild-type) Heterozygous Homozygous (variant)
No. (%)
CYP2E1*6 14 (88) 2 (12) 0 (0)
CYP2E1*5A 16 (100) 0 (0) 0 (0)
CYP2E1*5B 16 (100) 0 (0) 0 (0)
GSTM1*0* 10 (62) 6 (38)
GSTT1*0* 10 (62) 6 (38)
GSTP1 313A>G 6 (38) 9 (56) 1 (6)
GSTP1 341C>T 12 (74) 2 (13) 2 (13)
*Individuals homozygous for the null alleles of GSTM1 and GSTT1*0 were not concordant despite the same size of the respective groups.
Table 3. Formation of hemoglobin adducts of acrylamide and glycidamide following intake of 1 mg (geometric
mean dose: 13.9 Mmol) of acrylamide in a test meal (n = 16)
Parameter (unit) Study period Comparison between periods
Reference* CYP2E1
inhibition*
CYP2E1
induction*
CYP2E1
inhibition
c
CYP2E1
induction
c
AAVal-Hb
(pmol/g globin)
Pre-dose 39 (26%)
[40 (24-62)]
41 (26%)
[42 (20-59)]
42 (35%)
[45 (15-64)]
105% (97-115%) 109% (100-119%)
24 h post-dose 47 (20%)
[47 (35-65)]
54 (23%)
[55 (28-73)]
51 (33%)
[51 (20-75)]
114% (105-124%) 109% (100-118%)
Fold change 1.20 (12%)
[1.17 (1.03-1.64)]
1.30 (11%)
[1.27 (1.06-1.55)]
1.20 (10%)
[1.21 (0.99-1.20)]
108% (102-115%) 100% (94-106%)
GAVal-Hb
(pmol/g globin)
Pre-dose 28 (32%)
[29 (17-48)]
29 (31%)
[29 (17-47)]
30 (24%)
[29 (22-50)]
102% (90-115%) 107% (94-121%)
24 h post-dose 32 (21%)
[30 (23-48)]
30 (24%)
[30 (20-52)]
34 (24%)
[32 (22-57)]
94% (86-104%) 106% (96-117%)
Fold change
b
1.13 (24%)
[1.18 (0.78-1.54)]
1.04 (30%)
[1.03 (0.66-1.85)]
1.12 (26%)
[1.14 (0.61-1.59)]
93% (80-108%) 100% (86-116%)
Ratio GAVal-Hb/
AAVal-Hb
Pre-dose 0.72 (41%)
[0.75 (0.47-1.23)]
0.70 (41%)
[0.77 (0.31-1.41)]
0.71 (43%)
[0.66 (0.40-2.09)]
97% (83-112%) 99% (84-114%)
24 h post-dose 0.68 (28%)
[0.69 (0.43-1.03)]
0.56 (29%)
[0.54 (0.30-1.08)]
0.66 (41%)
[0.66 (0.29-1.78)]
83% (73-94%) 98% (86-111%)
Fold change
b
0.94 (25%)
[0.93 (0.64-1.43)]
0.80 (34%)
[0.80 (0.43-1.57)]
0.93 (32%)
[0.94 (0.45-1.61)]
86% (74-100%) 100% (86-116%)
NOTE: Significant differences between periods (i.e., unity not included in the confidence interval) are in boldface.
Abbreviations: AAVal, N-2-carbomoylethylvaline (AA adduct); GAVal, N-(R,S )-2-hydroxy-2-carbamoylethylvaline (GA adduct).
*Values are shown as geometric means (CV%) and [median(range)].
cValues are shown as point estimate and 90% confidence interval for the percent ratio relative to the reference period.
bPost/pre changes are significant when analyzed for all periods together.
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1 week, an increase in CYP2E1 activity of f30% was
expected in healthy subjects (59). We did not decide for a
higher dose for tolerability reasons because we wanted
neither to risk a potentially excessive formation of
glycidamide nor to interfere too much with daily
activities of the healthy volunteers. After 3 days of
alcohol abstinence, the CYP2E1 activity would be
assumed to return to baseline (59). We did not find any
significant changes in toxicokinetics of either unchanged
acrylamide or mercapturic acid metabolites and in
formation of hemoglobin adducts on chronic exposure
to ethanol. Assuming a predominant role of CYP2E1 in
acrylamide oxidation and anf30% increased in enzyme
activity under conditions used, expected changes in
acrylamide toxicokinetics would be only one third of
those observed for CYP2E1 inhibition by disulfiram. The
lack of differences in acrylamide toxicokinetics on
CYP2E1 induction of this magnitude, therefore, does
not exclude a role of CYP2E1 in acrylamide metabolism
because the intraindividual variability observed is too
high for detection of small differences.
Baseline hemoglobin adduct concentrations were
similar to those reported (27, 60-62). At 24 hours after
intake of a single 1-mg acrylamide dose, an increased
formation of both acrylamide and glycidamide adducts
to hemoglobin was observed. This suggests that vice
versa dietary interventions are helpful to reduce adduct
formation, whereas a beneficial effect of a modulation of
CYP2E1 activity is less clear. There were changes both in
the GAMA/AAMA ratio of acrylamide excretion excret-
ed in urine and in the ratio of GA-/AA-Val adducts to
hemoglobin during disulfiram coadministration. Both
parameters are proposed biomarkers of internal acryl-
amide exposure in humans (22, 27, 36), but it remains
uncertain how closely they are linked to formation of
tissue DNA adducts. In rodent studies, a good linear
correlation was reported between glycidamide adducts
to hemoglobin and liver glycidamide DNA adducts (16)
and between acrylamide adducts to hemoglobin and
acrylamide sperm DNA adducts (63). However, although
the epoxide glycidamide is considered as the ultimate
genotoxic agent, there may also be a direct risk caused by
acrylamide, which may be as important as that conferred
by glycidamide because glycidamide formation is not the
main metabolic pathway of acrylamide. Thus, the use of
ratios of GA- over AA-derived products probably are not
useful biomarkers to predict acrylamide cytotoxicity and
resulting health risk in humans for all situations.
For CYP2E1 phenotyping, chlorzoxazone was used
in the present study and the plasma ratio of 6-OH-
chlorzoxazone/chlorzoxazone at 2 hours post-dose
served as a metric for enzyme activity. Good tolerability
of the chlorzoxazone dose administered as well as
validity of the applied phenotyping metric has been
shown previously (50, 51). The plasma concentration
ratio of 6-OH-chlorzoxazone/chlorzoxazone at 2 h post-
dose was similar to that obtained in other phenotyping
studies with similar design (51), and an apparently
normal baseline CYP2E1 activity was present in all study
subjects. Controversial data exist with respect to the
CYP2E1 genotype-phenotype relationship. Haufroid and
coworkers (64) observed in healthy Caucasians (n = 31) a
trend to lower 6-OH-chlorzoxazone/chlorzoxazone plas-
ma ratios in subjects with CYP2E1*6 allele(s) compared
with wild-type subjects. In contrast, CYP2E1*5A , *5B, *6
alleles detected in 70 White Americans (65) as well as in
20 Caucasians and 20 Japanese (66) were not associated
with differences in chlorzoxazone clearance. These
conflicting results may arise due to the limited number
of subjects with the rare genotypes in all studies,
including the present investigation. The present study
was not specifically designed to detect such differences
for acrylamide pharmacokinetics but confirms that the
presence of a single CYP2E1*6 allele has no obvious
effect.
With respect to the frequencies of CYP2E1, GSTM1,
GSTT1 , and GSTP1 genotype distribution, the study
population did not show an obvious deviation from the
general Caucasian population (47, 67-74). Homozygous
deletion of the entire GSTM1 and/or GSTT1 gene as well
as a major single nucleotide polymorphism in GSTP1 did
not influence the toxicokinetics of acrylamide (Fig. 2),
showing that these individual enzymes play no exclusive
role in the acrylamide and glycidamide conjugation with
glutathione. Accordingly, an in vitro study showed no
influence of GSTM1 or GSTT1 on hemoglobin adduct
Figure 2. Effects of GSTP1 polymorphisms and GSTM1 or
GSTT1-null genotypes on acrylamide (AA) toxicokinetics.
Homozygous null genotypes are denoted as *0/*0; *A/*X
stands for *A/*0 or *A/*A genotypes.
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formation after exposure of human blood samples to
acrylamide and glycidamide (75). However, recently the
up-regulation of genes encoding GSTs was shown by
exposure of Caenorhabditis elegans to 500 mg/L acrylam-
ide, and proteomic analysis confirmed some involvement
of GSTs (26). Negative results from our study on the
influence of GSTs on acrylamide metabolism support the
hypothesis of a primarily nonenzymatic conjugation of
acrylamide and glycidamide with glutathione (75). In
addition, this metabolic step could be mediated by other
GSTs not investigated here.
In conclusion, the increased amounts of unchanged
acrylamide and AAMA excreted in urine together with
decreased acrylamide excretion of GAMA observed
during CYP2E1 blockade by disulfiram supports the
nonexclusive involvement of CYP2E1 in glycidamide
formation in humans. Based on quantitative changes in
acrylamide toxicokinetics on CYP2E1 inhibition, CYP2E1
probably accounts for one fourth of primary acrylamide
metabolism in humans. Individual CYP2E1 activity,
induction of CYP2E1, and polymorphisms of CYP2E1
had no clear effect on acrylamide toxicokinetics, most
probably because the corresponding differences in
enzyme activity are not large enough. GSTP1, GSTM1,
and GSTT1 enzymes play no major role in the acrylamide
and glycidamide conjugation with glutathione. No
obvious genetic risks or protective factors with regard
to acrylamide-metabolizing enzymes could be deter-
mined for exposed subjects.
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